Skip to main content
Premium Trial:

Request an Annual Quote

Life Tech Investing $18M to Expand Facility to Achieve cGMP Capabilities

NEW YORK (GenomeWeb News) – Life Technologies today announced it will invest $18 million to expand its facility in Pleasanton, Calif., where the company will implement current good manufacturing practice capabilities for its genetic analysis products.

The expansion will occur over multiple phases and is part of the Carlsbad, Calif.-based company's efforts to broaden its product portfolio addressing the molecular diagnostics market. The project will break ground in the second quarter of 2013.

In the first phase of the expansion, 10,000 square feet of space will be repurposed for the manufacture of molecular probes and primers under cGMP standards, Life Tech said. In subsequent phases, 30,000 square feet of space will be added during a one- to three-year period for the production of materials, following regulatory standards, for qPCR workflows in the clinical space.

Life Tech said that it currently has nine facilities that follow cGMP standards and are ISO 9001/13485-compliant for the manufacturing of products such as instruments, reagents, assays, cell culture media, and sera.

"The expansion of the Pleasanton facility and plan to achieve cGMP certification underscores our growth strategy in new markets and our commitment to win in genetic analysis from discovery to diagnosis," Mark Stevenson, president and COO of Life Tech, said.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more